Arcturus up 12% premarket on promising COVID-19 vaccine data

  • Thinly traded micro cap Arcturus Therapeutics (NASDAQ:ARCT) is up 12% premarket on light volume in reaction to positive immunogenicity data from a preclinical study of its COVID-19 vaccine candidate LUNAR-COV19.
  • According to CSO Pad Chivukula, Ph.D., the company's STARR mRNA is superior to conventional mRNA at equivalent doses and time points, adding that self-replicating mRNA "significantly" increases spike protein expression, yielding "many-fold" higher seroconversion rates suggesting that the 2 µg dose could potentially immunize millions more people.

Recommended For You

Comments (10)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.